Best Healthcare Stocks to Buy in 2026

Biogen posted Q1 revenue of $2.5 billion, up 2% year over year, with EPS jumping 31% to $2.15 and Leqembi sales rising 74% to $168 million; free cash flow also surged 167% to $594 million. Novo Nordisk reported first-quarter revenue of 96.8 billion DKK ($15.3 billion), up 24%, and operating profit up 54% to 59.6 billion DKK, while its valuation remains just under 11x earnings. The article is broadly constructive on both names, but favors Novo Nordisk for stronger growth, a 3.9% dividend yield, and continued portfolio expansion through acquisitions and label extensions.

Analysis

The market is still underestimating the optionality embedded in both names, but for different reasons. BIIB is a duration trade on a cleaner conversion of its neurology franchise into a broader cash-flow annuity: a more usable Leqembi format can matter more for adoption than headline efficacy because it lowers infusion-chair friction, expands prescriber willingness, and reduces abandonment at the patient level. NVO is a scale trade where the key question is not demand but how quickly it can monetize the installed base into adjacent metabolic indications before price competition and payer pushback compress future growth rates.

The second-order winner in BIIB is not just the company itself but the broader rare-disease pipeline ecosystem: if Apellis assets integrate smoothly, the market may start paying a higher multiple for bolt-on acquisitions that convert high-science, low-commercial-overhead assets into a large-cap sales force. The main loser is older MS cash generation, which is being masked by new-product enthusiasm; if legacy decline accelerates faster than Leqembi ramps, the stock will look cheap for a reason. For NVO, the real competitive pressure is supply-chain discipline: if manufacturing keeps pace, the company can defend share without heroic pricing, but any bottleneck instantly shifts share to peers and forces channel fill assumptions lower.

The market may also be too complacent about regulatory timing risk. For BIIB, a delay of weeks matters little, but a label or administration limitation would hit the adoption curve over the next 2-3 quarters because the addressable patient funnel is highly sensitive to convenience and caregiver burden. For NVO, the bear case is a normalization trade: once obesity growth decelerates from scarcity-driven to capacity-driven expansion, the multiple can compress even if revenue keeps rising, especially if investors stop treating GLP-1 as a category winner-take-most story.

Contrarianly, the better asymmetry may be in the pair rather than the outright longs. BIIB has more upside if execution is clean, but NVO has more defense if growth simply remains above consensus; the risk/reward likely favors owning NVO into any post-earnings volatility and using BIIB as a higher-beta catalyst trade. The consensus is missing how much of both stories depends on commercialization mechanics, not science: convenience, reimbursement, and fill rates will drive near-term revisions more than clinical headlines.

Key Decisions for Investors

• Long NVO on any 3-5% pullback over the next 2-6 weeks; use a 12-month horizon with upside driven by multiple support plus continued metabolic portfolio expansion. Risk/reward favors downside protection through cash generation and dividend yield.
• Trade BIIB as a catalyst long into the next regulatory update: buy a 1-3 month window on weakness, targeting a 15-20% re-rate if subcutaneous Leqembi is approved or priced as a near-term launch catalyst. Tighten risk if review timing slips materially beyond the current quarter.
• Pair trade: long NVO / short BIIB over 3-6 months to express quality growth over turnaround execution risk. NVO has more durable earnings visibility; BIIB’s upside is more dependent on regulatory and launch execution.
• For higher convexity, consider BIIB call spreads into the next FDA decision window. The thesis is that convenience-driven adoption can reaccelerate the stock if the market starts modeling a broader patient funnel, but the position should be defined-risk given binary timing uncertainty.
• Avoid chasing APLS and AKRO outright after the M&A headlines unless entry is materially below deal-implied valuation. The cleaner expression is via BIIB and NVO, where acquisition optionality is already embedded in operating cash flow rather than takeover premium.